Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07685639

Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study

The purpose of this study is to determine whether a proactive, EHR-guided approach helps more individuals reach safe cholesterol levels, improves medication use, and reduces future heart attacks and strokes, compared to usual care.

The main question it aims to answer is:

• Does the EHR-LOCALE pathway increases the proportion of patients who reach the LDL-cholesterol target of <1.8 mmol/L at 6 months?

Participants in the interventional group receive:

* Pharmacist contact * Repeat lipid requisitions * Review of medications, adherence, and side effects * Treatment escalation according to national dyslipidemia guidelines

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

ACS (Acute Coronary Syndrome) Acute Coronary Syndrome Cardiovascular Diseases Dyslipidemia Dyslipidemias Heart Diseases Hyperlipidemia Hyperlipidemias Lipid Metabolism Disorders Low-Density-Lipoprotein-cholesterol Level Metabolic Diseases Myocardial Ischemia Nutritional and Metabolic Diseases Vascular Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

After a heart event, such as a heart attack, many people never reach the cholesterol levels needed to lower their risk of experiencing another heart event even with good care. This research study is evaluating a new way to better support patients in reaching those targets. The EHR-LOCALE study uses Alberta's electronic health record (EHR) to automatically identify these individuals and offer them extra support. Those who are not at their cholesterol target are contacted by a pharmacist, who can order blood tests, review medications, and adjust treatment according to national guidelines.

This project tests whether this proactive, EHR-guided approach helps more patients reach safe cholesterol levels, improves medication use, and reduces future heart attacks and strokes, compared to usual care. Ultimately, it aims to make cholesterol management after a heart event more consistent, equitable, and effective.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults over the age of 18
  • Resident of Alberta
  • Individuals hospitalized with an acute coronary syndrome and have undergone coronary angiography.
  • Able to participate in follow-up contact if randomized to the intervention arm

Exclusion criteria

  • In-hospital mortality

Treatment and study plan

Pharmacist-led lipid optimization pathway

Other

Referral to a centralized, pharmacist-led, telephone clinic for optimization of dyslipidemia management

Primary outcomes

  1. Proportion of individuals who achieve guideline recommended low-density-lipoprotein (LDL) cholesterol target of <1.8 mmol/L at 6-months

    Time frame: From enrollment to the end of intervention at 6 months

Secondary outcomes

  1. Proportion of individuals with repeat lipid panel testing at 3-months and 6-months

    Time frame: From enrollment to the end of intervention at 6 months

  2. Proportion of individuals who undergo escalation or addition of new of lipid lowering therapies

    Time frame: From enrollment to the end of intervention at 6 months

  3. Absolute difference in lipid values (LDL-C, high-density lipoprotein-cholesterol [HDL-C], non-HDL cholesterol, triglycerides) at six-months

    Time frame: From enrollment to the end of intervention at 6 months

  4. Composite of all-cause mortality, hospitalization for myocardial infarction, hospitalization for stroke and unplanned coronary revascularization at one-year and five-years

    Time frame: From enrollment to 1 year and 5 years

Other outcomes

  1. Cost-effectiveness of a centralized, EHR-augmented dyslipidemia management pathway following an ACS

    Time frame: From enrollment to the end of intervention at 6 months

Study contacts

Contact information is provided by the study sponsor or research team.

Canadian VIGOUR Centre

CONTACT

[email protected]

(800) 707-9098

Sponsors and collaborators

Lead sponsor

University of Alberta

Other

Registry information

Acronym: EHR-LOCALE

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 6, 2026
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.